SCHEMBL3526804

SCHEMBL3526804

CCc1cc(O)c(C(=O)O)cc1CC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 3/20 0.47
CSNK2A1 P68400 1/20 0.47
ALOX12 P18054 1/20 0.47
KLKB1 P03952 1/20 0.45
CTSB P07858 1/20 0.45
MMP9 P14780 1/20 0.45
DNMT1 P26358 1/20 0.45
DNMT3B Q9UBC3 1/20 0.45
DNMT3L Q9UJW3 1/20 0.45
DNMT3A Q9Y6K1 1/20 0.45
CA1 P00915 3/20 0.45
CA2 P00918 3/20 0.45
ALDH1A1 P00352 3/20 0.45
CA12 O43570 2/20 0.45
CA7 P43166 2/20 0.45
CA9 Q16790 2/20 0.45
CA14 Q9ULX7 2/20 0.45
PTGS2 P35354 2/20 0.45
ALOX5 P09917 1/20 0.45
TSHR P16473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12553675 0.89 MAPT (0.53) ALOX15CSNK2A1ALOX12KLKB1CTSB
SCHEMBL31335625 0.89 MAPT (0.53) ALOX15CSNK2A1ALOX12KLKB1CTSB
SCHEMBL3834007 0.89 CSNK2A1 (0.45) ALOX15CSNK2A1KLKB1CTSBMMP9
SCHEMBL4116012 0.85 GABRP (0.50) ALOX15CSNK2A1ALOX12ALDH1A1TSHR
SCHEMBL14273018 0.84 GABRP (0.47) ALOX15CSNK2A1ALOX12KLKB1CTSB
SCHEMBL18339211 0.84 TSHR (0.43) ALOX15CSNK2A1ALOX12KLKB1CTSB
SCHEMBL14316411 0.82 KLKB1 (0.45) ALOX15CSNK2A1KLKB1CTSBMMP9
Butane SCHEMBL8165642 0.81 ALDH1A1 (0.54) ALOX15CSNK2A1KLKB1CTSBMMP9
Alcohol SCHEMBL28690211 0.81 CSNK2A1 (0.50) ALOX15CSNK2A1KLKB1CTSBMMP9
SCHEMBL31336022 0.81 HMGCR (0.54) CA1CA2ALDH1A1CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-20060229336-A1 Ccr5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORPORATION 2006-10-12 US disclosed
CN-1744899-A Piperidine derivatives as CCR5 antagonists SMITHKLINE BEECHAM CORP (US) 2006-03-08 CN disclosed
EP-1569646-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2005-09-07 EP disclosed
WO-2004054974-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229336-A1 Ccr5 antagonists as therapeutic agents CCR5, CCR1, CXCR3 ALOX15 1639/4885CSNK2A1 3364/4885ALOX12 2311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.